Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers

Florence Coussy; Elise Deluche; Barbara Pistilli; Sylvain Ladoire; Jean Marc Ferrero; Paul Cottu

doi:10.1016/j.bulcan.2021.04.007

Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers

Florence Coussy, Elise Deluche, Barbara Pistilli, Sylvain Ladoire, Jean Marc Ferrero, Paul Cottu

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

The historical median survival of advanced luminal breast cancer does not exceed four years. The deciphering of the mechanisms of resistance to hormone therapy has led to the development of inhibitors of cyclin D dependent kinases (CDK4 and 6). Three drugs, palbociclib, ribociclib and abemaciclib, very similar pharmacologically, have been evaluated in the context of pivotal, randomized phase III trials. Strikingly and regardless of the endocrine therapy backbone, and in both hormone-sensitive and hormone-resistant patients, the addition of a CDK4 / 6 inhibitor doubles progression-free survival with a hazard ratio always around 0.55. The benefit in overall survival begins to be demonstrated. This review presents all published results, as well as the main safety data.

Translated title of the contribution	Place des inhibiteurs de kinases dépendantes des cyclines 4/6 dans la prise en charge du cancer du sein avancé
Original language	English
Pages (from-to)	843-854
Number of pages	12
Journal	Bulletin du Cancer
Volume	108
Issue number	9
DOIs	https://doi.org/10.1016/j.bulcan.2021.04.007
Publication status	Published - 1 Sept 2021

Keywords

Advanced breast cancer
CDK4/6 inhibitor

Access to Document

10.1016/j.bulcan.2021.04.007

Cite this

@article{f166cefbb2d946ec99a1bd56df1fbd8a,

title = "Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers",

abstract = "The historical median survival of advanced luminal breast cancer does not exceed four years. The deciphering of the mechanisms of resistance to hormone therapy has led to the development of inhibitors of cyclin D dependent kinases (CDK4 and 6). Three drugs, palbociclib, ribociclib and abemaciclib, very similar pharmacologically, have been evaluated in the context of pivotal, randomized phase III trials. Strikingly and regardless of the endocrine therapy backbone, and in both hormone-sensitive and hormone-resistant patients, the addition of a CDK4 / 6 inhibitor doubles progression-free survival with a hazard ratio always around 0.55. The benefit in overall survival begins to be demonstrated. This review presents all published results, as well as the main safety data.",

keywords = "Advanced breast cancer, CDK4/6 inhibitor",

author = "Florence Coussy and Elise Deluche and Barbara Pistilli and Sylvain Ladoire and Ferrero, {Jean Marc} and Paul Cottu",

note = "Publisher Copyright: {\textcopyright} 2021 Soci{\'e}t{\'e} Fran{\c c}aise du Cancer",

year = "2021",

month = sep,

day = "1",

doi = "10.1016/j.bulcan.2021.04.007",

language = "English",

volume = "108",

pages = "843--854",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "9",

}

TY - JOUR

T1 - Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers

AU - Coussy, Florence

AU - Deluche, Elise

AU - Pistilli, Barbara

AU - Ladoire, Sylvain

AU - Ferrero, Jean Marc

AU - Cottu, Paul

PY - 2021/9/1

Y1 - 2021/9/1

N2 - The historical median survival of advanced luminal breast cancer does not exceed four years. The deciphering of the mechanisms of resistance to hormone therapy has led to the development of inhibitors of cyclin D dependent kinases (CDK4 and 6). Three drugs, palbociclib, ribociclib and abemaciclib, very similar pharmacologically, have been evaluated in the context of pivotal, randomized phase III trials. Strikingly and regardless of the endocrine therapy backbone, and in both hormone-sensitive and hormone-resistant patients, the addition of a CDK4 / 6 inhibitor doubles progression-free survival with a hazard ratio always around 0.55. The benefit in overall survival begins to be demonstrated. This review presents all published results, as well as the main safety data.

AB - The historical median survival of advanced luminal breast cancer does not exceed four years. The deciphering of the mechanisms of resistance to hormone therapy has led to the development of inhibitors of cyclin D dependent kinases (CDK4 and 6). Three drugs, palbociclib, ribociclib and abemaciclib, very similar pharmacologically, have been evaluated in the context of pivotal, randomized phase III trials. Strikingly and regardless of the endocrine therapy backbone, and in both hormone-sensitive and hormone-resistant patients, the addition of a CDK4 / 6 inhibitor doubles progression-free survival with a hazard ratio always around 0.55. The benefit in overall survival begins to be demonstrated. This review presents all published results, as well as the main safety data.

KW - Advanced breast cancer

KW - CDK4/6 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85108269123&partnerID=8YFLogxK

U2 - 10.1016/j.bulcan.2021.04.007

DO - 10.1016/j.bulcan.2021.04.007

M3 - Review article

C2 - 34154797

AN - SCOPUS:85108269123

SN - 0007-4551

VL - 108

SP - 843

EP - 854

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 9

ER -

Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers

Abstract

Keywords

Access to Document

Other files and links

Cite this